Teligene US clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-14
What changed in the last 30 days
3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.
- Notable: TL938 and Trastuzumab · HER2-positive Metastatic Colorectal Cancer Primary completion pushed from Oct 2026 to Dec 2028
- Minor: Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC Trial sites expanded: 9 → 24 locations
- Minor: Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer Enrollment increased: 99 → 128 participants
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 2 | 4 |
Disease areas by active trials
Lung Cancer (2) · Non-Small Cell Lung Cancer (NSCLC) (2) · Colorectal Cancer (1)
Get alerts when Teligene US's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.